These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246 [TBL] [Abstract][Full Text] [Related]
26. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Yang C; Sun MG; Matro J; Huynh TT; Rahimpour S; Prchal JT; Lechan R; Lonser R; Pacak K; Zhuang Z Blood; 2013 Mar; 121(13):2563-6. PubMed ID: 23361906 [TBL] [Abstract][Full Text] [Related]
27. Ocular manifestations of hypoxia-inducible factor-2α paraganglioma-somatostatinoma-polycythemia syndrome. Pacak K; Chew EY; Pappo AS; Yang C; Lorenzo FR; Wilson MW; Aronow MB; Young JA; Popovic V; Zhuang Z Ophthalmology; 2014 Nov; 121(11):2291-3. PubMed ID: 25109928 [No Abstract] [Full Text] [Related]
28. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310 [TBL] [Abstract][Full Text] [Related]
29. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840 [TBL] [Abstract][Full Text] [Related]
30. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation. Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974 [TBL] [Abstract][Full Text] [Related]
31. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. Toledo R; Jimenez C F1000Res; 2018; 7():. PubMed ID: 30109021 [TBL] [Abstract][Full Text] [Related]
32. A Rare Case of Paraganglioma Syndrome Associated With Polycythemia and Blindness. Esaki Y; Liao X; Harbuz-Miller I Cureus; 2024 Jun; 16(6):e63047. PubMed ID: 39050329 [TBL] [Abstract][Full Text] [Related]
33. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Lorenzo FR; Yang C; Ng Tang Fui M; Vankayalapati H; Zhuang Z; Huynh T; Grossmann M; Pacak K; Prchal JT J Mol Med (Berl); 2013 Apr; 91(4):507-12. PubMed ID: 23090011 [TBL] [Abstract][Full Text] [Related]
34. HIF2 and endocrine neoplasia: an evolving story. Maher ER Endocr Relat Cancer; 2013 Jun; 20(3):C5-7. PubMed ID: 23653463 [TBL] [Abstract][Full Text] [Related]
35. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. Tella SH; Taïeb D; Pacak K Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040 [TBL] [Abstract][Full Text] [Related]
37. Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome. Wang H; Zhuang Z; Rosenblum JS; Pacak K Endocr Pract; 2022 Jul; 28(7):734-735. PubMed ID: 35489703 [No Abstract] [Full Text] [Related]
38. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901 [TBL] [Abstract][Full Text] [Related]
39. Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas. Jones RB; Cohen DL Curr Cardiol Rep; 2023 Nov; 25(11):1451-1460. PubMed ID: 37847359 [TBL] [Abstract][Full Text] [Related]
40. Functional significance of germline EPAS1 variants. Dwight T; Kim E; Bastard K; Benn DE; Eisenhofer G; Richter S; Mannelli M; Rapizzi E; Prejbisz A; Pęczkowska M; Pacak K; Clifton-Bligh R Endocr Relat Cancer; 2021 Feb; 28(2):97-109. PubMed ID: 33300499 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]